Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Influenza A Virus Infection Induces Viral and Cellular Defective Ribosomal Products Encoded by Alternative Reading Frames.

Zanker DJ, Oveissi S, Tscharke DC, Duan M, Wan S, Zhang X, Xiao K, Mifsud NA, Gibbs J, Izzard L, Dlugolenski D, Faou P, Laurie KL, Vigneron N, Barr IG, Stambas J, Van den Eynde BJ, Bennink JR, Yewdell JW, Chen W.

J Immunol. 2019 May 15. pii: ji1900070. doi: 10.4049/jimmunol.1900070. [Epub ahead of print]

PMID:
31092636
2.

The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.

Ma W, Stroobant V, Heirman C, Sun Z, Thielemans K, Mulder A, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2019 Jan 15;202(2):451-459. doi: 10.4049/jimmunol.1800353. Epub 2018 Dec 17.

PMID:
30559321
3.

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.

Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R, Vannucci J, Mondanelli G, Ludovini V, Ferri I, Bianconi F, Del Sordo R, Cagini L, Albini E, Metro G, Puma F, Sidoni A.

Virchows Arch. 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17.

PMID:
30448912
4.

Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.

Zhu J, Petit PF, Van den Eynde BJ.

Cancer Immunol Immunother. 2019 May;68(5):835-847. doi: 10.1007/s00262-018-2269-y. Epub 2018 Nov 7. Review.

PMID:
30406374
5.

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.

Gomes B, Driessens G, Bartlett D, Cai D, Cauwenberghs S, Crosignani S, Dalvie D, Denies S, Dillon CP, Fantin VR, Guo J, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Pirson R, Rabolli V, Ray C, Streiner N, Torti VR, Tsaparikos K, Van den Eynde BJ, Wythes M, Yao LC, Zheng X, Tumang J, Kraus M.

Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19.

PMID:
30232146
6.

Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Vigneron N, Ferrari V, Van den Eynde BJ, Cresswell P, Leonhardt RM.

J Immunol. 2018 Oct 1;201(7):1875-1888. doi: 10.4049/jimmunol.1701479. Epub 2018 Aug 22.

PMID:
30135181
7.

Production of spliced peptides by the proteasome.

Vigneron N, Stroobant V, Ferrari V, Abi Habib J, Van den Eynde BJ.

Mol Immunol. 2018 Apr 9. pii: S0161-5890(18)30109-3. doi: 10.1016/j.molimm.2018.03.030. [Epub ahead of print]

PMID:
29650230
8.

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ.

Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.

9.

Peptide splicing by the proteasome.

Vigneron N, Ferrari V, Stroobant V, Abi Habib J, Van den Eynde BJ.

J Biol Chem. 2017 Dec 22;292(51):21170-21179. doi: 10.1074/jbc.R117.807560. Epub 2017 Nov 6. Review.

10.

Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.

Vigneron N, Abi Habib J, Van den Eynde BJ.

Trends Cancer. 2017 Oct;3(10):726-741. doi: 10.1016/j.trecan.2017.07.007. Epub 2017 Aug 24. Review.

PMID:
28958390
11.

Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.

Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, Plaen E, Van den Eynde BJ.

Cancer Immunol Res. 2017 Aug;5(8):695-709. doi: 10.1158/2326-6066.CIR-16-0400. Epub 2017 Jul 21.

12.

Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P.

Trends Immunol. 2017 Aug;38(8):577-593. doi: 10.1016/j.it.2017.05.006. Epub 2017 Jun 10. Review.

PMID:
28610825
13.

Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes.

Ebstein F, Textoris-Taube K, Keller C, Golnik R, Vigneron N, Van den Eynde BJ, Schuler-Thurner B, Schadendorf D, Lorenz FK, Uckert W, Urban S, Lehmann A, Albrecht-Koepke N, Janek K, Henklein P, Niewienda A, Kloetzel PM, Mishto M.

Sci Rep. 2016 Apr 6;6:24032. doi: 10.1038/srep24032.

14.

Long-Peptide Cross-Presentation by Human Dendritic Cells Occurs in Vacuoles by Peptide Exchange on Nascent MHC Class I Molecules.

Ma W, Zhang Y, Vigneron N, Stroobant V, Thielemans K, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2016 Feb 15;196(4):1711-20. doi: 10.4049/jimmunol.1501574. Epub 2016 Jan 20.

15.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

16.

Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan.

van Baren N, Van den Eynde BJ.

Cancer Immunol Res. 2015 Sep;3(9):978-85. doi: 10.1158/2326-6066.CIR-15-0095. Epub 2015 Aug 12. Review.

17.

The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors.

Vigneron N, Abi Habib J, Van den Eynde BJ.

Data Brief. 2015 May 18;4:146-51. doi: 10.1016/j.dib.2015.04.019. eCollection 2015 Sep.

18.

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.

Vigneron N, van Baren N, Van den Eynde BJ.

Oncoimmunology. 2015 Feb 3;4(5):e1003012. eCollection 2015 May.

19.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

20.

Heterogeneity of synovial molecular patterns in patients with arthritis.

Lauwerys BR, Hernández-Lobato D, Gramme P, Ducreux J, Dessy A, Focant I, Ambroise J, Bearzatto B, Nzeusseu Toukap A, Van den Eynde BJ, Elewaut D, Gala JL, Durez P, Houssiau FA, Helleputte T, Dupont P.

PLoS One. 2015 Apr 30;10(4):e0122104. doi: 10.1371/journal.pone.0122104. eCollection 2015.

21.

The capture proteasome assay: A method to measure proteasome activity in vitro.

Vigneron N, Abi Habib J, Van den Eynde BJ.

Anal Biochem. 2015 Aug 1;482:7-15. doi: 10.1016/j.ab.2015.04.019. Epub 2015 Apr 23.

PMID:
25912419
22.

Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.

Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona C, Fallarino F, De Somer L, Tousseyn T, Quartier P, Wouters C, Matthys P.

Rheumatology (Oxford). 2015 Aug;54(8):1507-17. doi: 10.1093/rheumatology/keu524. Epub 2015 Mar 12.

PMID:
25767156
23.

Tryptophan-degrading enzymes in tumoral immune resistance.

van Baren N, Van den Eynde BJ.

Front Immunol. 2015 Feb 3;6:34. doi: 10.3389/fimmu.2015.00034. eCollection 2015. Review.

24.

Early Posttransplant Tryptophan Metabolism Predicts Long-term Outcome of Human Kidney Transplantation.

Vavrincova-Yaghi D, Seelen MA, Kema IP, Deelman LE, van der Heuvel MC, Breukelman H, Van den Eynde BJ, Henning RH, van Goor H, Sandovici M.

Transplantation. 2015 Aug;99(8):e97-104. doi: 10.1097/TP.0000000000000603.

PMID:
25651307
25.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

26.

Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.

Vigneron N, Van den Eynde BJ.

Biomolecules. 2014 Nov 18;4(4):994-1025. doi: 10.3390/biom4040994. Review.

27.

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ.

Cancer Immunol Res. 2015 Feb;3(2):161-72. doi: 10.1158/2326-6066.CIR-14-0137. Epub 2014 Sep 30.

28.

Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Röhrig UF, Majjigapu SR, Chambon M, Bron S, Pilotte L, Colau D, Van den Eynde BJ, Turcatti G, Vogel P, Zoete V, Michielin O.

Eur J Med Chem. 2014 Sep 12;84:284-301. doi: 10.1016/j.ejmech.2014.06.078. Epub 2014 Jul 10.

PMID:
25036789
29.

Endosomal compartment: Also a dock for MHC class I peptide loading.

Ma W, Van den Eynde BJ.

Eur J Immunol. 2014 Mar;44(3):650-3. doi: 10.1002/eji.201444470.

30.

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T.

Nat Rev Cancer. 2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Review.

PMID:
24457417
31.

A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming.

Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N.

J Immunol. 2014 Feb 15;192(4):1962-71. doi: 10.4049/jimmunol.1302032. Epub 2014 Jan 22.

32.

Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.

Vandermeulen G, Uyttenhove C, De Plaen E, Van den Eynde BJ, Préat V.

Bioelectrochemistry. 2014 Dec;100:112-8. doi: 10.1016/j.bioelechem.2013.11.002. Epub 2013 Dec 1.

PMID:
24342164
33.

Database of T cell-defined human tumor antigens: the 2013 update.

Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P.

Cancer Immun. 2013 Jul 15;13:15. Print 2013. Review.

34.

Identifying source proteins for MHC class I-presented peptides.

Vigneron N, Ma W, Michaux A, Van den Eynde BJ.

Methods Mol Biol. 2013;960:187-207. doi: 10.1007/978-1-62703-218-6_16.

PMID:
23329489
35.

Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus.

Badot V, Luijten RK, van Roon JA, Depresseux G, Aydin S, Van den Eynde BJ, Houssiau FA, Lauwerys BR.

Ann Rheum Dis. 2013 Mar;72(3):453-6. doi: 10.1136/annrheumdis-2012-202364. Epub 2012 Dec 22.

36.

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.

Platten M, Wick W, Van den Eynde BJ.

Cancer Res. 2012 Nov 1;72(21):5435-40. doi: 10.1158/0008-5472.CAN-12-0569. Epub 2012 Oct 22. Review.

37.

Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Zhu S, Van den Eynde BJ, Coulie PG, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Immunother. 2012 Nov-Dec;35(9):680-8. doi: 10.1097/CJI.0b013e31827338ea.

38.

Analysis of the processing of seven human tumor antigens by intermediate proteasomes.

Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Parmentier N, Dalet A, Van den Eynde BJ.

J Immunol. 2012 Oct 1;189(7):3538-47. Epub 2012 Aug 27.

39.

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.

Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N.

Eur J Immunol. 2012 Jun;42(6):1417-28. doi: 10.1002/eji.201141954.

40.

Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.

Röhrig UF, Majjigapu SR, Grosdidier A, Bron S, Stroobant V, Pilotte L, Colau D, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.

J Med Chem. 2012 Jun 14;55(11):5270-90. doi: 10.1021/jm300260v. Epub 2012 May 22.

PMID:
22616902
41.

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502. doi: 10.1073/pnas.1113873109. Epub 2012 Jan 30.

42.

Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity.

Vigneron N, Van den Eynde BJ.

Curr Opin Immunol. 2012 Feb;24(1):84-91. doi: 10.1016/j.coi.2011.12.002. Epub 2011 Dec 27. Review.

PMID:
22206698
43.

Minimal tolerance to a tumor antigen encoded by a cancer-germline gene.

Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, Pilotte L, Powis de Tenbossche CG, Chomez P, Brasseur F, Schmitt-Verhulst AM, Van den Eynde BJ.

J Immunol. 2012 Jan 1;188(1):111-21. doi: 10.4049/jimmunol.1002612. Epub 2011 Dec 2.

44.

An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):E323-31. doi: 10.1073/pnas.1101892108. Epub 2011 Jun 13.

45.

Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.

Vigneron N, Van den Eynde BJ.

Cell Mol Life Sci. 2011 May;68(9):1503-20. doi: 10.1007/s00018-011-0658-x. Epub 2011 Mar 9. Review.

PMID:
21387143
46.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

47.

A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.

Ma W, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJ.

Int J Cancer. 2011 Nov 15;129(10):2427-34. doi: 10.1002/ijc.25911. Epub 2011 Apr 20.

48.

Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome.

Dalet A, Stroobant V, Vigneron N, Van den Eynde BJ.

Eur J Immunol. 2011 Jan;41(1):39-46. doi: 10.1002/eji.201040750. Epub 2010 Dec 9.

49.

Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines.

Badot V, Durez P, Van den Eynde BJ, Nzeusseu-Toukap A, Houssiau FA, Lauwerys BR.

J Cell Mol Med. 2011 Nov;15(11):2335-42. doi: 10.1111/j.1582-4934.2010.01228.x.

50.

Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.

Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch MP, Théate I, Parmentier N, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. doi: 10.1073/pnas.1009778107. Epub 2010 Oct 11.

Supplemental Content

Loading ...
Support Center